360 ONE Asset, the asset management arm of the former IIFL Wealth group, has acquired a minority stake in House of Diagnostics, one of North India’s fastest growing integrated diagnostics chains. The investment, completed in mid January 2026, is part of 360 ONE’s strategy to deploy capital into high conviction sectors with strong structural tailwinds diagnostics being a standout beneficiary of rising healthcare awareness, chronic disease prevalence, and increasing insurance penetration in India.

House of Diagnostics operates more than 100 centres across Delhi-NCR, Haryana, Uttar Pradesh, Punjab, and Rajasthan, providing a full spectrum of pathology, radiology, cardiology diagnostics, and imaging services. The chain is known for its focus on quality (NABL and NABH accreditations), rapid turnaround times, and affordable pricing, serving both walk-in patients and large hospital partners.

The investment will enable House of Diagnostics to accelerate its expansion into underserved tier-2 and tier-3 cities, upgrade laboratory and imaging infrastructure with AI-driven automation, enhance digital patient engagement platforms, and strengthen supply chain and operational efficiencies. The company has already embarked on a multi-year plan to double its network size while maintaining high standards of accuracy and service reliability.

Dr. Ashish Monga, Managing Director of House of Diagnostics, commented: “This partnership with 360 ONE Asset is a strong validation of our model and growth trajectory. Their support will help us scale faster, invest in cutting-edge technology, and reach more patients with reliable, affordable diagnostics especially in areas where organised healthcare is still emerging.”

360 ONE Asset brings not only capital but also strategic guidance on scaling operations, governance, and long-term value creation. The investment aligns with the firm’s thesis that India’s organised diagnostics sector currently a mix of fragmented regional players and national chains offers significant consolidation and growth potential as patients increasingly seek quality, transparency, and convenience.

The Indian diagnostics market is estimated to grow at a CAGR of 12–15% over the next decade, driven by preventive health checkups, chronic disease management, and government schemes such as Ayushman Bharat. Organised players like House of Diagnostics are well positioned to capture share from unorganised labs through superior quality, faster reporting, digital integration, and patient trust.

This transaction reflects a broader trend of private equity and asset management firms increasingly participating in India’s healthcare services space particularly in diagnostics, primary care, and hospital chains where scalable models with strong unit economics are emerging.